St. Petersburg Times
Special report
Video report
  • For their own good
    Fifty years ago, they were screwed-up kids sent to the Florida School for Boys to be straightened out. But now they are screwed-up men, scarred by the whippings they endured. Read the story and see a video and portrait gallery.
  • More video reports
Multimedia report
Print Email this storyEmail story Comment Email editor
Fill out this form to email this article to a friend
Your name Your email
Friend's name Friend's email
Your message
 

Health and medicine

FDA okays new breast cancer drug

Associated Press
Published December 29, 2005


Women now have another drug they can take to prevent breast cancer from returning after surgery to remove the tumor.

The Food and Drug Administration on Wednesday approved a new use for Femara, a medication already licensed for treating advanced breast cancer. It now can be given as initial therapy to women past menopause who have early breast cancer, the agency said.

In today's New England Journal of Medicine, a study reports that Femara was more effective at preventing recurrences than the current gold standard, tamoxifen.

Femara and Arimidex, a similar drug already licensed, are aromatase inhibitors, which block production of estrogen, a hormone that fuels the growth of most tumors that develop after menopause. Tamoxifen works differently, by blunting the ability of estrogen to enter cells.

The study estimated 84 percent of women given Femara versus 81 percent of those on tamoxifen would have no signs of cancer five years after starting treatment.

The estimates were based on two years of information on relapses among the 8,000 women in the study.

[Last modified December 29, 2005, 00:52:13]


Share your thoughts on this story

[an error occurred while processing this directive]
Subscribe to the Times
Click here for daily delivery
of the St. Petersburg Times.

Email Newsletters

ADVERTISEMENT